# BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 Statement of Cash Flows

- Company: BIOCRYST PHARMACEUTICALS, INC. (BCRX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-053300
- Page: https://plicit.ai/financials/bcrx/fy2026-ytd-q2-cash-flow
- Chart image: https://plicit.ai/charts/bcrx-fy2026-ytd-q2-cash-flow-sankey.png

## Chart details

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Dec 31, 2025**: 91,337,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- **Operating activities**: 42,551,000 US dollars. Net cash provided.
- **Net (loss) income**: negative 643,417,000 US dollars
- **Depreciation**: 974,000 US dollars
- **Acquired in-process research and development**: 697,761,000 US dollars
- **Amortization of assembled workforce**: 600,000 US dollars
- **Inventory obsolescence**: 583,000 US dollars
- **Stock-based compensation expense**: 30,719,000 US dollars
- **Mark-to-market adjustment on share-based liability**: 3,331,000 US dollars
- **Payment of Pharmakon paid-in-kind interest**: 0 US dollars
- **Non-cash interest expense on royalty financing obligations**: 26,330,000 US dollars
- **Amortization of debt issuance costs on term loans**: 352,000 US dollars
- **Amortization of discount on investments, net**: negative 166,000 US dollars
- **Loss on extinguishment of debt**: 0 US dollars
- **Increase in trade receivables**: negative 1,959,000 US dollars
- **(Increase) decrease in inventory**: negative 9,196,000 US dollars
- **Decrease in prepaid expenses and other assets**: 7,964,000 US dollars
- **Decrease in royalty financing obligations**: negative 26,788,000 US dollars
- **Decrease in accounts payable and accrued expenses**: negative 55,330,000 US dollars
- **Increase in deferred revenue**: 10,793,000 US dollars
- **Investing activities**: negative 378,796,000 US dollars. Net cash used.
- **Acquisitions of property and equipment**: negative 612,000 US dollars
- **Purchases of investments**: negative 135,635,000 US dollars
- **Sales and maturities of investments**: 246,931,000 US dollars
- **Acquisition of Astria Therapeutics, Inc., net of cash acquired**: negative 489,480,000 US dollars
- **Financing activities**: 401,399,000 US dollars. Net cash provided.
- **Net proceeds from common stock issued under stock-based compensation plans**: 25,682,000 US dollars
- **Withholding taxes paid on stock-based awards**: negative 4,879,000 US dollars
- **Common stock issued to directors in lieu of cash retainer**: 77,000 US dollars
- **Proceeds from term loan**: 400,000,000 US dollars
- **Repayment of Pharmakon term loan principal**: 0 US dollars
- **Prepayment premium and fees on Pharmakon term loan**: 0 US dollars
- **Payment of debt issuance costs on term loan**: negative 4,952,000 US dollars
- **Principal payments on royalty financing obligations**: negative 13,823,000 US dollars
- **Principal payments on finance lease liabilities**: negative 706,000 US dollars
- **Operating adjustment reconciliation**: 779,407,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 425,759,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 625,727,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: 0 US dollars
- **Other changes in cash (calculated)**: negative 107,000 US dollars. Out of cash; drawn as the small gray flow above ending cash.
- **Ending cash on Jun 30, 2026**: 156,384,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- **Cash sources and uses**: 535,287,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: 65,047,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
- **Operating cash flow**: 42,551,000 US dollars. Operating cash flow used in the free cash flow calculation.
- **cash spent on productive assets**: 612,000 US dollars. These cash purchases are already included in investing activities above.
- **Free cash flow**: 41,939,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net loss −$643.42M + net operating adjustments $685.97M = operating cash +$42.55M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash spent on productive assets equals free cash flow: 42,551,000 US dollars minus 612,000 US dollars equals 41,939,000 US dollars.